141 related articles for article (PubMed ID: 31087297)
1. Assessment of SIRT2 Inhibitors in Mouse Models of Cancer.
Negrón Abril YL; Fernández I; Weiss RS
Methods Mol Biol; 2019; 1983():151-171. PubMed ID: 31087297
[TBL] [Abstract][Full Text] [Related]
2. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
Spiegelman NA; Price IR; Jing H; Wang M; Yang M; Cao J; Hong JY; Zhang X; Aramsangtienchai P; Sadhukhan S; Lin H
ChemMedChem; 2018 Sep; 13(18):1890-1894. PubMed ID: 30058233
[TBL] [Abstract][Full Text] [Related]
3. A Glycoconjugated SIRT2 Inhibitor with Aqueous Solubility Allows Structure-Based Design of SIRT2 Inhibitors.
Hong JY; Price IR; Bai JJ; Lin H
ACS Chem Biol; 2019 Aug; 14(8):1802-1810. PubMed ID: 31373792
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors.
Hong JY; Fernandez I; Anmangandla A; Lu X; Bai JJ; Lin H
ACS Chem Biol; 2021 Jul; 16(7):1266-1275. PubMed ID: 34139124
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors.
Yang L; Ma X; Yuan C; He Y; Li L; Fang S; Xia W; He T; Qian S; Xu Z; Li G; Wang Z
Eur J Med Chem; 2017 Jul; 134():230-241. PubMed ID: 28415012
[TBL] [Abstract][Full Text] [Related]
6. Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity.
Shah AA; Ito A; Nakata A; Yoshida M
Biol Pharm Bull; 2016; 39(10):1739-1742. PubMed ID: 27725455
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening studies to identify novel selective SIRT2 inhibitors.
Eren G; Bruno A; Guntekin-Ergun S; Cetin-Atalay R; Ozgencil F; Ozkan Y; Gozelle M; Kaya SG; Costantino G
J Mol Graph Model; 2019 Jun; 89():60-73. PubMed ID: 30870650
[TBL] [Abstract][Full Text] [Related]
8. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
9. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer.
Hoffmann G; Breitenbücher F; Schuler M; Ehrenhofer-Murray AE
J Biol Chem; 2014 Feb; 289(8):5208-16. PubMed ID: 24379401
[TBL] [Abstract][Full Text] [Related]
10. Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT.
Yagci S; Gozelle M; Kaya SG; Ozkan Y; Aksel AB; Bakar-Ates F; Dundar Y; Eren G
Bioorg Med Chem; 2021 Jan; 30():115961. PubMed ID: 33360574
[TBL] [Abstract][Full Text] [Related]
11. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.
Roshdy E; Mustafa M; Shaltout AE; Radwan MO; Ibrahim MAA; Soliman ME; Fujita M; Otsuka M; Ali TFS
Eur J Med Chem; 2021 Nov; 224():113709. PubMed ID: 34303869
[TBL] [Abstract][Full Text] [Related]
12. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from a SIRT2-selective inhibitor.
Jing H; Lin H
Oncotarget; 2016 Apr; 7(17):22971-2. PubMed ID: 27050282
[No Abstract] [Full Text] [Related]
14. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.
Jing H; Hu J; He B; Negrón Abril YL; Stupinski J; Weiser K; Carbonaro M; Chiang YL; Southard T; Giannakakou P; Weiss RS; Lin H
Cancer Cell; 2016 Mar; 29(3):297-310. PubMed ID: 26977881
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress on the Discovery of Sirt2 Inhibitors for the Treatment of Various Cancers.
Wang T; Xu Z; Lu Y; Shi J; Liu W; Zhang C; Jiang Z; Qi B; Bai L
Curr Top Med Chem; 2019; 19(12):1051-1058. PubMed ID: 31074370
[TBL] [Abstract][Full Text] [Related]
16. Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
Farooqi AS; Hong JY; Cao J; Lu X; Price IR; Zhao Q; Kosciuk T; Yang M; Bai JJ; Lin H
J Med Chem; 2019 Apr; 62(8):4131-4141. PubMed ID: 30986062
[TBL] [Abstract][Full Text] [Related]
17. Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner.
McCarthy AR; Sachweh MC; Higgins M; Campbell J; Drummond CJ; van Leeuwen IM; Pirrie L; Ladds MJ; Westwood NJ; Laín S
Mol Cancer Ther; 2013 Apr; 12(4):352-60. PubMed ID: 23322738
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors.
Khalil NA; Ahmed EM; Zaher AF; El-Zoghbi MS; Sobh EA
Eur J Med Chem; 2020 Feb; 187():111926. PubMed ID: 31812033
[TBL] [Abstract][Full Text] [Related]
19. Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
Galli U; Mesenzani O; Coppo C; Sorba G; Canonico PL; Tron GC; Genazzani AA
Eur J Med Chem; 2012 Sep; 55():58-66. PubMed ID: 22835719
[TBL] [Abstract][Full Text] [Related]
20. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
